Bill

Bill > HR6321


US HR6321

US HR6321
Lung Cancer Medicare Access to Precise Testing Act


summary

Introduced
11/28/2025
In Committee
11/28/2025
Crossed Over
Passed
Dead

Introduced Session

119th Congress

Bill Summary

A BILL To amend title XVIII of the Social Security Act to require coverage of lung cancer biomarker testing under the Medicare program.

AI Summary

This bill aims to require Medicare to cover lung cancer biomarker testing starting January 1, 2027. Specifically, the bill amends the Social Security Act to define lung cancer biomarker testing as a diagnostic test performed on an individual with lung cancer that identifies specific biomarkers (such as genes, proteins, or molecules) through analysis of tissue, blood, or bodily fluids. The legislation mandates that Medicare will pay 100% of the reasonable charges for this type of testing, ensuring that patients diagnosed with lung cancer can access precise diagnostic tools without financial burden. By adding this type of testing to Medicare's covered services, the bill seeks to improve early detection and potentially personalized treatment strategies for lung cancer patients by enabling more detailed molecular-level diagnostic information.

Committee Categories

Business and Industry

Sponsors (4)

Last Action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (on 11/28/2025)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...